|
|
Article: Adolor Licenses Six Opioid- Related Patents From Eli Lilly.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Adolor Corp. licensed six patents from Eli Lilly and Co. to help develop products related to peripherally selective opioid antagonists.
Exton, Pa.-based Adolor paid Lilly $4 million on the signing of the deal and agreed to pay clinical and regulatory milestones as well as royalties to Lilly if products develop from the research. Peter Schied, Adolor's chief financial officer, told BioWorld Today that the company focuses on opioid technology.
"Our lead product is in this area, so acquisition of the rest of this technology increases our opportunity to further develop products," he said.
Alvimopan, Adolor's lead product ...